BACKGROUND: Multiantibiotic-resistant bacteria pose a threat to patients and place an economic burden on health care systems. Carbapenem-resistant bacilli and extended-spectrum ␤-lactamase (ESBL) producers drive the need to screen infected and colonized patients for patient management and infection control.
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Multidrug resistant organisms (MDROs) 1 are a growing concern globally. Every year, Ͼ2 million Americans are infected with antibiotic-resistant bacteria, resulting in 23 000 deaths because of a lack of therapeutic options to combat these bacteria (1 ) . Associated annual direct health care costs exceed $20 billion in the US (1 ). Gramnegative MDROs are especially worrisome, according to the Centers for Disease Control and Prevention (CDC), which reports that carbapenemase-resistant Enterobacteriaceae (CRE) have been found in medical facilities in 47 of the 50 states, with major outbreaks occurring in the Northeast, Chicago, and Denver (2 ) .
Because clinical cultures usually identify only a fraction of all patients with CRE, the CDC recommends a range of CRE screening measures to identify carriers and prevent the spread of infection, including (a) point prevalence surveys of patients and health care providers in hospitals and long-term care facilities; (b) active surveillance testing of prespecified high-risk patients (e.g., intensive care and long-term care); and (c) epidemiological linkage of colonized carriers and infected patients (3 ) . Asymptomatic individuals and patients colonized with MDROs are reservoirs for transmission (4 ) . During an outbreak at the NIH Clinical Center, for example, a carbapenem-resistant Klebsiella pneumoniae (KPC) strain that affected 18 patients, 11 of whom died, resided undetected in the facility for 3 weeks between patient transmissions (5 ) .
␤-Lactamases are the primary threat of antibiotic resistance among gram-negative MDROs, as categorized by penicillinases, extended-spectrum ␤-lactamases (ESBLs), and carbapenemases, on the basis of degradation of penicillins, cephalosporins, monobactams, and carbapenems. Genes for KPC, New Delhi metallo-␤-lactamase (NDM), Verona integron-mediated metallo-␤-lactamase (VIM), and inosine monophosphate (IMP) encode serine and metallo-␤-lactamases with carbapenemase and broad-spectrum inhibition of antibiotics. Increased prevalence of carbapenemases has been identified in gram-negative bacilli, including Klebsiella spp., Escherichia coli, Enterobacter spp., Acinetobacter spp., Pseudomonas aeruginosa, Citrobacter freundii, Serratia marcescens, Salmonella enterica, Raoultella spp., and Proteus mirabilis. KPC is associated with mortality rates of Ͼ50% in the US (6 ), whereas NDM, VIM, and IMP are associated with mortality rates of 18%-67% (5 ). The OXA gene family codes a diverse set of ␤-lactamases against penicillins, cephalosporins, and carbapenems. The CTX-M gene family represents the most common ESBLs among Enterobacteriaceae worldwide, with the US recently experiencing a rapid emergence and spread of K. pneumoniae and E. coli expressing CTX-M (7 ).
The vanA operon encodes Enterococci resistance to vancomycin and teicoplanin in Enterococcus faecalis, E. faecium, E. gallinarum, E. casseliflavus, E. durans, E. raffinosus, and E. avium (8 ) . Identifying asymptomatic carriers is essential to controlling vancomycin-resistant Enterococci in hospitals and long-term care facilities.
We describe the Acuitas ® MDRO Gene Test (OpGen) for detection of antibiotic resistance gene families (KPC, NDM, VIM, IMP, OXA-23, OXA-48, OXA-51, CTX-M-1, CTX-M-2, and VanA) associated with MDROs including CREs, carbapenem-resistant gram-negative bacilli, and ESBLs, plus vancomycinresistant Enterococci. The multiplex microfluidic PCR test provides sensitive, specific, and high-throughput analysis of perianal swab samples from infected or colonized patients as an aid to health care, patient management, and infection control in diagnostic or surveillance settings where identification of infected and colonized patients can minimize transmission and reduce outbreaks.
Materials and Methods

SAMPLE EXTRACTION
Perianal swabs were collected with the BD Liquid Amies Elution Swab (ESwab) Collection and Transport System (#480C), a sample collection device that is designed to release bacterial organisms from the swab into 1 mL transport media during sample transport. We extracted total nucleic acids from 500 L transport media per ESwab with the MagNA Pure 96 DNA and Viral NA Large Volume Kit (P/N 06374891001, Roche) on the MagNA Pure 96 System, which produces 100 L extracted nucleic acids from each perianal swab sample.
PCR
Nested PCR was performed with outside primers for the first PCR (see Supplemental Table 1 , which accompanies the online version of this article at http://www. clinchem.org/content/vol62/issue2) followed by inside primers and a fluorescent reporter probe for the second PCR (see online Supplemental Table 2 ). PCR primers and fluorescent reporter probes were designed against homologous sequences within gene families and contained degenerate nucleotides to cover several subtypes per gene family. Fluorescent reporter probes were Applied Biosystems Custom TaqMan ® MGB™ Probes with 5Ј-FAM™ and a 3Ј nonfluorescent quencher. All PCRs used dUTP instead of TTP along with uracil-DNA glycosylase before the first multiplex PCR to guard against accidental amplicon contamination. We prepared an internal amplification control (gBlocks Gene Fragment from Integrated DNA Technologies) in 1 g/mL calf thymus DNA in Tris-EDTA, pH 8 (Fisher BP2473-1), that was added to all samples before PCR to monitor potential PCR inhibition.
We performed the first step of nested PCR as 3 separate multiplex PCRs per perianal swab sample (see online Supplemental Table 1 Table 1 ), and 1ϫ Express qPCR Supermix Universal master mix (11785-01K, Life Technologies). We added the internal amplification control to all samples at 100 molecules per PCR. PCR was performed with the following cycling program: 2 min at 50°C, 10 min at 95°C, and 25 cycles of 15 s at 95°C, 1 min at 61°C, followed by incubation at 4°C.
We combined 5-L aliquots from each of the 3 completed multiplex PCRs per perianal swab sample, along with 6 L of 4 U/L E. coli exonuclease I in 1ϫ buffer (M0293S, New England Biolabs) for a final volume of 21 L per perianal swab sample. Exonuclease digestion occurred at 37°C for 30 min with subsequent exonuclease inactivation at 80°C for 15 min. Each exonuclease-treated sample was diluted to 75 L with 10 mmol/L Tris and 1 mmol/L EDTA, pH 7.8. Aliquots (2.6 nL) from each resulting sample served as targets for the second PCR detection step.
The second PCR detection step (see online Supplemental Table 2 ) was performed with the BioMark HD System and 192.24 Dynamic Array Integrated Fluidic Circuit (Fluidigm), which is a microfluidic array capable of analyzing 192 samples with 24 separate PCR assays. Each PCR on the circuit contained 2.6 nL target from the first PCR step, plus 900 nmol/L of each inside PCR primer, 200 -500 nmol/L fluorescent reporter probe (see online Supplemental Table 2 ), and 1ϫ FastStart Universal Probe Master Mix (Rox) (P/N 04914139001, Roche) with MgCl 2 supplemented to an additional 3 mmol/L. PCR was performed with the following cycling program: 10 min at 95°C and 30 cycles of 15 s at 95°C, 1 min at 60°C, followed by incubation at 4°C.
SENSITIVITY TESTING
We demonstrated clinical analytical sensitivity for each gene family assay by spiking a pool of negative perianal swab samples from human volunteers with mixtures of clinical bacterial organisms (IHMA and ATCC). Perianal swab samples were collected under approval by OpGen's Internal Review Board. We estimated the number of spiked bacterial cells per perianal swab sample by parallel counting of colony forming units (CFU) on culture plates (BD Trypticase™ Soy Agar with 5% Sheep Blood, TSA II™) as follows. We created 0.5 McFarland standards from individual bacterial cultures for each organism and then prepared 10 serial 10-fold dilutions in 1ϫ PBS (BP2438 -20, Fisher) from each 0.5 McFarland standard. We used 100 L from each serial dilution to inoculate blood agar plates with overnight incubation at 37°C. The number of bacterial colonies per agar plate was used to calculate the number of CFU per mL for each serial dilution, which in turn was used to calculate spiked CFU per perianal swab sample. Only agar plates with 10 -300 colonies were used to estimate CFU levels. Each spiked perianal swab sample containing a mixture of bacterial organisms at estimated CFU levels underwent DNA extraction in duplicate and subsequent testing in triplicate. Limits of detection were defined as the lowest CFU level per perianal swab for each bacterial organism where all 6 test replicates were positive for the appropriate gene family assay.
GENE SPECIFICITY TESTING
We tested gene specificity for each gene family assay by use of 265 clinical bacterial organisms (IHMA and ATCC) with a variety of antibiotic-resistance genotypes. We prepared individual 0.5 McFarland standards from individual bacterial cultures per organism and then prepared 3 serial 10-fold dilutions in 1ϫ PBS from each 0.5 McFarland standard. We tested 500 L from the third serial dilution for each clinical organism, which represented approximately 10 6 CFU per sample. Each spiked sample was extracted and tested in duplicate. Acuitas MDRO Gene Test results were compared with reported genotypes from IHMA and reference PCR results (9 -11 ) . Reference PCR results for gene families CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-9, and CTX-M-25 were also obtained (Beta-Lactamase Detection, Comprehensive Gram-negative Bacteria Panel, Test Code 91334, Quest).
REPRODUCIBILITY TESTING
Analytical intra-and interday reproducibility was demonstrated by use of negative perianal swab samples spiked with mixtures of clinical bacterial organisms harboring ␤-lactamase genes as described above for sensitivity testing. Each spiked clinical organism was present at approximately 100 -10 000 CFU per perianal swab sample as indicated. Each spiked swab sample was prepared in triplicate and tested in duplicate (6 replicates) on each of 3 days, each day by 1 of 2 blinded laboratory technicians.
Results
The Acuitas MDRO Gene Test was designed to detect the vancomycin-resistance gene vanA plus hundreds of gene subtypes from the carbapenemase and ESBL families KPC, NDM, VIM, IMP, OXA-23, OXA-48, OXA-51, CTX-M-1, and CTX-M-2, regardless of the bacterial species harboring the antibiotic resistance. Table 1 indicates the antibiotic resistance gene subtypes for which each gene family assay was designed. PCR primers and probes are perfect matches for all reported subtypes of the KPC and NDM gene families, along with most reported subtypes for the gene families VIM, IMP, OXA-23, OXA-48, OXA-51, CTX-M-1, and CTX-M-2 as described in Table 1 . The test was not designed to distinguish subtypes within the gene families KPC, NDM, VIM, IMP, OXA-23, OXA-48, OXA-51, CTX-M-1, and CTX-M-2. The test uses nested PCR with real-time PCR detection in a microfluidic array. The first PCR step was performed as 3 separate multiplex PCRs per perianal swab sample ( Fig. 1) with the following gene targets per multiplex PCR: (a) KPC, NDM, VIM, and the internal amplification control; (b) OXA-51, OXA-23, OXA-48, VanA, and IMP; and (c) CTX-M-1 and CTX-M-2. The 3 completed PCR samples were pooled and treated with exonuclease to remove primers, with the resulting sample serving as target for a series of real-time detection PCRs on the 192.24 Dynamic Array Integrated Fluidic Circuit, which is a microfluidic array capable of analyzing 192 samples with 24 separate PCR assays. The test was designed for operation in a central testing laboratory receiving hundreds of samples per day, analyzing as many as 182 patient samples in a single laboratory shift.
TEST SENSITIVITY
We determined clinical analytical sensitivity of the test in our CLIA-certified laboratory by collecting negative perianal swab samples from human volunteers and quantitatively spiking the samples with clinical bacterial organisms harboring ␤-lactamase genes (e.g., E. cloacae with gene subtype KPC-3) as shown in Table 2 . Spiked levels of the clinical organisms were determined by parallel counting of bacterial CFU on agar culture plates. The test exhibited limits of detection of 11-250 CFU per perianal swab sample across the gene family assays (Table 2) . Because only 5% of the anal swab sample was analyzed in the test, the corresponding PCR sensitivity was 0.6 -13 CFU per PCR, where detection of Ͻ1 CFU reflects detection of dead bacteria plus target antibiotic resistance genes carried on multiple plasmid copies per bacterial cell. The test exhibited analytical sensitivity of approximately 10 target molecules per PCR when evaluated by use of synthetic PCR targets (gBlocks Gene Fragment, Integrated DNA Technologies) (data not shown). 
isolates lacking target genes or harboring additional antibiotic-resistance genes for which the test was not designed (e.g., OXA-24, OXA-72, CTX-M-8, CTX-M-9, CTX-M-14, CTX-M-27, CTX-M-65, SHV, TEM, ACT, MIR, CMY, DHA, ACT, and VEB). The test was negative for 99 clinical organisms lacking reported antibiotic-resistance genes. The presence and absence of the vanA gene in 33 vancomycin-resistant and 24 vancomycin-sensitive Enterococci were also correctly detected. Gene specificity results are shown in online Supplemental Table 3 for a representative set of 265 clinical organisms with a variety of antibiotic-resistance genes.
TEST REPRODUCIBILITY
We demonstrated intra-and intertest reproducibility over 3 days by use of negative perianal swab samples quantitatively spiked with mixtures of clinical bacterial organisms harboring target resistance genes. Swab samples were spiked with mixtures of bacterial organisms from Table 2 at approximately 100, 1000, or 10 000 CFU per spiked sample for each organism. Each spiked swab sample was prepared in triplicate and tested in duplicate (6 replicates) on each of 3 days. The range of PCR cycle threshold values across the 6 replicates is shown in Table 3 for each gene family assay over 3 days of testing. The test exhibited reproducible and quantitative results for all 10 antibiotic resistance genes across a range of target levels, although the test was not designed to be quantitative in clinical practice, because of the nonquantitative nature of sample collection with perianal swabs. The VanA assay exhibited poorer sensitivity and reproducibility compared with the other assays (Tables 2  and 4 ). For instance, negative VanA results were obtained for 1 of 6 replicates on each day of reproducibility testing at the lowest spiked level of approximately 100 CFU per swab sample (Table 3) , which is below the assay's limit of detection of 250 CFU per sample reported in Table 1 . The VanA assay was evaluated by use of perianal swab samples spiked with the gram-positive organism E. faecium, whereas the other assays were evaluated via spiking with gram-negative organisms ( Table 2 ). The VanA assay was found to be as sensitive and reproducible as the other assays when evaluated by use of synthetic PCR targets (gBlocks Gene Fragments, Integrated DNA Technologies) (data not shown). Assay performance would be expected to be influenced by the efficiency of sample extraction for gram-positive vs -negative and/or target gene copy numbers. VanA tends to be a single-copy chromosomal gene, whereas ␤-lactamase genes are typically carried on plasmids at approximately 2-10 copies per bacterial cell.
Discussion
We have described a sensitive and high-throughput multiplex molecular diagnostic test that is provided through (11, 12 ) plus the 2 most common gene families of ESBLs (CTX-M-1 and CTX-M-2) (13 ), along with the vancomycin resistance gene vanA, which is prevalent across clinical strains of E. faecalis and E. faecium. The test also detected all subtypes of the KPC and NDM gene families along with the vast majority of subtypes for the gene families VIM, IMP, OXA-23, OXA-48, OXA-51, CTX-M-1, and CTX-M-2 as curated by databases such as the Lahey Clinic (http://www.lahey.org/studies/ other.asp#Table1). The test thereby provides broad multiplex coverage for the most common and critical carbapenemase and ESBL genes from clinical gram-negative bacilli across the world while maintaining essential detection sensitivity. Future versions of the test may include additional albeit less prevalent ESBL genes (e.g., CTX-M-9) plus cephalosporinase and AmpC ␤-lactamase genes for broader coverage of antibiotic-resistant gramnegative bacilli.
The test was designed for high-throughput screening in a central testing laboratory receiving hundreds of samples per day. Results from 182 patient samples (1820 reported gene tests results) were obtained with high sensitivity in a single laboratory shift to meet the clinical demands of molecular diagnostic screening for bacterial colonization of perianal swab samples.
MDROs in hospitals and long-term care facilities pose a serious threat to patient health and a challenge to patient management. According to the CDC, antibioticresistant bacteria, especially CRE, are among the most serious health threats to the US population, leading to death in Յ50% of patients who become infected (1 ) . Recent emergence of dangerous carbapenem-resistant bacilli and ESBL producers with transmissible plasmids has accelerated the need for the development of new methods to diagnose infected patients, screen high-risk individuals, and track infection outbreaks.
A report from the Agency for Healthcare Research and Quality suggests that active screening programs can effectively control MDRO prevalence when they identify colonized patients and place them into contact isolation precautions (14 ) . Further, traditional infection-control strategies that only target monitoring of clinical isolates as a trigger for initiating control interventions have not proved effective for KPC control, and are only addressing the tip of the iceberg, since there are about 100 colonized patients for every infected patient (14 ) .
Clinical evidence suggests that asymptomatic individuals and patients colonized with MDROs are especially problematic. One study found that healthy patients who tested positive for carbapenem-resistant A. baumannii cultures had 8.4 times the risk of developing a subsequent infection than patients who remained negative on surveillance cultures (15 ) . In another study, 32 of 433 patients (7.4%) with carbapenem-resistant K. pneumoniae developed an infection within 2-40 days from colonization to infection (16 ) .
The CDC recommends that providers use a range of CRE screening measures to identify carriers and prevent the spread of infection (1 ) . Current clinical methods, such as microbe detection on the basis of growing cells in a laboratory culture, a process that can take up to 4 days, may identify only a fraction of all patients with CREs. Investigators in a study of 36 patients with CRE bloodstream infections reported that time to treatment had a significant effect on the course of infection, with rectal screening leading to earlier recognition and prompt empirical treatment (17 ) .
The Acuitas MDRO Gene Test (OpGen) represents a sensitive and high-throughput tool to assist patient management in health care settings through surveillance testing or diagnosis of actively infected patients, with excellent sensitivity and gene coverage for the most common carbapenemase and ESBL genes.
